About grail - GRAL
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
GRAL At a Glance
GRAIL, Inc.
1525 O'Brien Drive
Menlo Park, California 94025
| Phone | 1-833-694-2553 | Revenue | 125.60M | |
| Industry | Medical Specialties | Net Income | -2,027,005,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 34.896% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,000 | |
| View SEC Filings |
GRAL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.817 |
| Price to Book Ratio | 0.242 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.159 |
| Enterprise Value to Sales | -0.719 |
| Total Debt to Enterprise Value | -0.754 |
GRAL Efficiency
| Revenue/Employee | 125,595.00 |
| Income Per Employee | -2,027,005.00 |
| Receivables Turnover | 5.097 |
| Total Asset Turnover | 0.033 |
GRAL Liquidity
| Current Ratio | 10.658 |
| Quick Ratio | 10.416 |
| Cash Ratio | 9.925 |
GRAL Profitability
| Gross Margin | -62.122 |
| Operating Margin | -579.443 |
| Pretax Margin | -1,721.694 |
| Net Margin | -1,613.922 |
| Return on Assets | -52.654 |
| Return on Equity | -65.923 |
| Return on Total Capital | -78.824 |
| Return on Invested Capital | -64.615 |
GRAL Capital Structure
| Total Debt to Total Equity | 2.722 |
| Total Debt to Total Capital | 2.65 |
| Total Debt to Total Assets | 2.168 |
| Long-Term Debt to Equity | 2.192 |
| Long-Term Debt to Total Capital | 2.134 |